The clinical consequences of routine ⁶⁸Ga-PSMA-11 PET/CT in patients with newly diagnosed prostate cancer, ISUP grade 5 and no metastases based on standard imaging – preliminary results

References

• Afshar-Oromieh A, Haberkorn U, Eder M, et al. [68Ga]gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39(6):1085–1086.
   PubMed Web of Science ®Google Scholar
• Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197–209.
   PubMed Web of Science ®Google Scholar
• Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective Single-Arm clinical trial. JAMA Oncol. 2019;5(6):856.
   PubMed Web of Science ®Google Scholar
• Petersen LJ, Zacho HD. PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review. Cancer imaging: the official publication of the international cancer imaging. Cancer Imaging. 2020;20(1):10.
   PubMedGoogle Scholar
• Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208–1216.
   PubMed Web of Science ®Google Scholar
• Mottet PC N, van den Bergh RCN, Briers E. members of the EAU – ESTRO – ESUR –SIOG Prostate Cancer Guidelines Panel. EAU – ESTRO – ESUR – SIOG Guidelines on Prostate Cancer. https://uroweborg/guideline/prostate-cancer/?type=archive. 2020.
   Google Scholar
• Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic efficacy of (68)Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195(5):1436–1443.
   PubMed Web of Science ®Google Scholar
• van Leeuwen PJ, Emmett L, Ho B, et al. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int. 2017;119(2):209–215.
   PubMed Web of Science ®Google Scholar
• Hope TA, Goodman JZ, Allen IE, et al. Metaanalysis of (68)Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med. 2019;60(6):786–793.
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–629.
   PubMed Web of Science ®Google Scholar
• Zacho HD, Manresa JAB, Aleksyniene R, et al. Three-minute SPECT/CT is sufficient for the assessment of bone metastasis as add-on to planar bone scintigraphy: prospective head-to-head comparison to 11-min SPECT/CT. EJNMMI Res. 2017;7(1):1.
   PubMedGoogle Scholar
• Nielsen JB, Zacho HD, Haberkorn U, et al. A comprehensive safety evaluation of 68Ga-Labeled ligand Prostate-Specific membrane antigen 11 PET/CT in prostate cancer: the results of 2 prospective, multicenter trials. Clin Nucl Med. 2017;42(7):520–524.
   PubMedGoogle Scholar
• Fendler WP, Calais J, Allen-Auerbach M, et al. 68)Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: An international multicenter prospective study. J Nucl Med. 2017;58(10):1617–1623.
   PubMed Web of Science ®Google Scholar
• Pyka T, Okamoto S, Dahlbender M, et al. Comparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(12):2114–2121.
   PubMed Web of Science ®Google Scholar
• Zacho HD, Ravn S, Afshar-Oromieh A, et al. Added value of (68)Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous (99m)Tc bone scintigraphy. EJNMMI Res. 2020;10(1):31.
   PubMed Web of Science ®Google Scholar
• Lengana T, Lawal IO, Boshomane TG, et al. 68)Ga-PSMA PET/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli? Clin Genitourin Cancer. 2018;16(5):392–401.
   PubMed Web of Science ®Google Scholar
• Calais J, Fendler WP, Eiber M, et al. Impact of (68)Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence. J Nucl Med. 2018;59(3):434–441.
   PubMed Web of Science ®Google Scholar
• Han S, Woo S, Kim YJ, et al. Impact of (68)Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and Meta-analysis. Eur Urol. 2018;74(2):179–190.
   PubMed Web of Science ®Google Scholar
• Emmett L, van Leeuwen PJ, Nandurkar R, et al. Treatment outcomes from (68)Ga-PSMA PET/CT-Informed salvage radiation treatment in men with rising PSA After radical prostatectomy: Prognostic value of a negative PSMA PET. J Nucl Med. 2017;58(12):1972–1976.
   PubMed Web of Science ®Google Scholar
• Suardi N, Porter CR, Reuther AM, et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer. 2008;112(6):1254–1263.
   PubMed Web of Science ®Google Scholar
• Engel J, Bastian PJ, Baur H, et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. European Urology. 2010;57(5):754–761.
   PubMedGoogle Scholar
• Steuber T, Budäus L, Walz J, et al. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. BJU Int. 2011;107(11):1755–1761.
   PubMed Web of Science ®Google Scholar
• Ranasinghe W, Chapin BF, Kim IY, et al. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU Int. 2020;125(6):792–800.
   PubMed Web of Science ®Google Scholar
• Yaxley JW, Raveenthiran S, Nouhaud FX, et al. Risk of metastatic disease on (68) gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU Int. 2019;124(3):401–407.
   PubMed Web of Science ®Google Scholar
• James ND, Sydes MR, Clarke NW, STAMPEDE investigators, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–1177.
   PubMed Web of Science ®Google Scholar
• James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. The. N Engl J Med. 2017;377(4):338–351.
   PubMed Web of Science ®Google Scholar
• Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353–2366.
   PubMed Web of Science ®Google Scholar